Preclinical

14 July 2020 SCIEX has celebrated its 50th anniversary with a digital product launch. SCIEX virtual product experience introduced products that enable customers to Run Fast, Go Beyond and Power Up. “Half a century ago, SCIEX set out with a mission to develop analytical technologies for aerospace. Today, our technologies cover analysis of environmental hazards, […]

The Translational Research Institute-based Mater researchers in partnership with The University of Queensland have developed a new cancer vaccine, which has shown promising signs in preclinical laboratory studies. Funded by grants from the Worldwide Cancer Research in the United Kingdom, and Mater Foundation, the new vaccine could be potentially used to treat a variety of blood […]

9 July 2020 Image: Science in HD So far there are no approved drugs for Non-Alcoholic Fatty Liver Disease In an effort to combat a growing worldwide epidemic of Nonalcoholic Fatty Liver Disease (NAFLD), scientists have discovered a new target and a new therapy that has shown promising results in preclinical mouse models, according to […]

23 June 2020 Image: Austin Distel The Innovation Credit is awarded by the Dutch government through its agency RVO of the Ministry of Economic Affairs and Climate Policy and is aimed at the development of promising and challenging innovations. The €3.1million fund will support the preclinical development of novel QPCTL (Glutaminyl-peptide cyclotransferase-like) inhibitors, completing the […]

18 May, 2020 The research-driven pharmaceutical company said the new acquisition provides assets targeting the tumour stroma and myeloid cells. Boehringer Ingelheim also announced it is collaborating with CDR-Life to develop antibody fragment-based therapeutics for geographic atrophy, a leading cause of blindness. The first programme, now in late preclinical development, is an antibody inhibitor of […]

Meeting analytical challenges in a brave new world of next generation biotherapeutics By Mani Krishnan and Susan Darling Volume 21 Issue 2 – Spring 2020 The need for innovative advanced analytical tools to accelerate the development of immunotherapies and other complex biologics that may one day cure genetic diseases and cancer has never been greater. […]

ADCs and solid tumours – The payload revolution that drives therapeutic opportunities in unmet need By Dr Jenny Thirlway Volume 21 Issue 2 – Spring 2020 The fight against cancer is ongoing. Despite progress in many indications, mortality rates for some of the most difficult to treat solid tumour types have not improved substantially since […]

Drug development 2.0 – The partnership model in practice By Dr Brian Sheehan and Marco Cerato Over the last decade there has been a fundamental shift in the way in which drugs are developed and brought to market. Some years ago, the industry started to see profits falling as research and development (R&D) costs continued […]

Cryo-EM accelerates drug discovery by delivering previously intractable structural insights By Hans Raaijmakers, et al. Cryo-electron microscopy (cryo-EM), a powerful biophysical technique that can analyse molecular assemblies, is changing the paradigm in structure-based drug design. As targets become more challenging, solving structures of drug target molecules or biologics becomes increasingly difficult. Cryo-EM empowers drug discovery […]

Evolution of User Experience for life sciences By Jacek Ziemski, Simon Fortenbacher, James Hoeksma, Jan Taubert, Roger Attrill, Paula de Matos, Andre Richter and Julie Morrison Since 2017 we have seen the slow and steady adoption of User Experience (UX) within the life sciences. User Experience is an evidence-based design process that centres on the […]